Dihexa (PNB-0408) — N-hexanoic-Tyr-Ile-(6) aminohexanoic amide angiotensin IV analog
In short
Angiotensin IV analog activating HGF/c-Met signaling, studied in models of synaptogenesis and cognitive function.
Overview
Dihexa is a synthetic oligopeptide derived from angiotensin IV that potently enhances cognitive function by promoting synaptogenesis. Originally developed at Washington State University for Alzheimer's disease, it's 7 orders of magnitude more potent than
Dihexa binds to hepatocyte growth factor (HGF) with high affinity and potentiates its activity at c-Met receptor, activating PI3K/AKT pathways. This promotes formation of new synaptic connections at levels 10 million times more potent than . Crosses blood-brain barrier effectively via oral or injectable routes.
Molecular information
Research indications
Grouped by area. Each entry reflects a separate published hypothesis or clinical signal - not medical advice.
McCoy et al. (J Pharmacol Exp Ther 2013) - oral administration raises dendritic spine density 5-7x in aged rats - result stronger than most pro-cognitive interventions.
Dihexa не е одобрен от и представлява само изследователско съединение. Съществува теоретичен риск от рак чрез активиране на c-Met. Липсват данни за дългосрочна безопасност при хора. Избягвайте употреба при анамнеза за рак. Не е подходящ за бременни или кърмещи жени. Може да причини свръхстимулация или тревожност. Изисква циклично приложение за предотвратяване на толерантност. Спрете употребата при тежки или постоянни главоболия, нарастваща тревожност или паника. Прекратете при значителни промени в настроението, депресия или нарушения на съня над 3 дни. Следете за всякакви тревожни неврологични симптоми, признаци на мания или реакции на мястото на инжектиране. Винаги се консултирайте с медицински специалист за насоки.
3 peer-reviewed sources
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
McCoy - Spine density
Animal | oral | various | +5-7x dendritic spine density
J Pharmacol Exp Ther · 2013
View the studyInformation about Dihexa is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAdipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadNo comments yet. Be the first.
Comments are reviewed before publishing.
